TRT and Liver Function: What Men Need to Know About Hepatotoxicity and ALT/AST Monitoring

For decades, the phrase "testosterone liver damage" has circulated in online forums and casual medical advice. There's good reason: early oral testosterone formulations did cause serious hepatotoxicity. But modern TRT delivers testosterone through routes that bypass or significantly reduce hepatic exposure, and the safety profile today is dramatically different from it was in the 1960s and 70s.

\n\n

This article covers what the evidence actually shows about testosterone and liver function, which formulations carry hepatic risk, how liver enzymes work on TRT blood work panels, and the monitoring cadence that responsible prescribing clinicians follow.

\n\n

Why Historical Oral Testosterone Damaged the Liver

\n\n

Oral testosterone in its native form (testosterone itself, not a modified ester) is rapidly broken down by the liver during first-pass metabolism. This means that nearly all of the dose is destroyed before it reaches systemic circulation. To achieve therapeutic blood levels, early pharmaceutical companies used chemically modified forms called 17-alpha-alkylated testosterone derivatives — including methyltestosterone, fluoxymesterone, and oxandrolone.

\n\n

These modifications allowed the molecule to survive first-pass metabolism, but at a cost. 17-alpha-alkylated steroids are well-documented to cause:

\n\n

\n
• Hepatotoxicity: Direct liver cell injury manifesting as elevated ALT and AST levels.
\n
• Cholestatic jaundice: Impaired bile flow causing bilirubin buildup.
\n
• Peliosis hepatis: A rare but serious condition involving blood-filled cysts in the liver, documented in long-term users of 17-alpha-alkylated oral anabolic steroids.
\n
• Hepatic tumors: Both benign (hepatocellular adenoma) and malignant tumors have been reported with prolonged use of methyltestosterone.
\n

\n\n

The FDA label for methyltestosterone specifically notes that "jaundice, hepatic dysfunction, and, rarely, hepatic neoplasms and peliosis hepatis have occurred after long-term use of 17-alpha-alkylated steroids." This is the origin of the testosterone-liver concern, and the warning remains valid for these specific compounds.

\n\n

Why Modern TRT Formulations Are Different

\n\n

The vast majority of TRT today does not use 17-alpha-alkylated oral testosterone. Instead, three delivery routes dominate, each with a different relationship to liver metabolism:

\n\n

Injections (Testosterone Cypionate, Enanthate, Undecanoate)

\n

Injectable testosterone bypasses first-pass hepatic metabolism entirely. The drug is absorbed into systemic circulation from the injection site (whether subcutaneous or intramuscular) and then metabolized — but the liver processes it the same way it processes endogenous testosterone. Injectable TRT is not associated with hepatotoxicity in the published literature.

\n\n

Transdermal (Gels, Creams, Patches)

\n

Skin-delivered testosterone also bypasses first-pass hepatic metabolism. Testosterone diffuses through the skin into systemic circulation. Like injectables, transdermal TRT does not carry a hepatotoxicity risk comparable to 17-alpha-alkylated oral compounds.

\n\n

Modern Oral Testosterone Undecanoate (Jatenzo, Tlando, Kyzatrex)

\n

The newer FDA-approved oral testosterone formulations use testosterone undecanoate, an esterified form absorbed through the lymphatic system rather than via portal circulation. This lymphatic absorption pathway bypasses first-pass hepatic metabolism. Post-approval clinical trials and real-world data have generally shown that oral TU does not produce the hepatocellular injury pattern seen with 17-alpha-alkylated steroids.

\n\n

That said, the FDA did note a blood pressure increase signal with oral TU in its approval review, and the prescribing information for Jatenzo and Tlando recommends blood pressure monitoring. Direct hepatotoxicity has not been a prominent safety signal for these products in post-marketing surveillance through 2025.

\n\n

When Liver Enzymes Can Still Shift on TRT

\n\n

Even though modern TRT doesn't inherently damage the liver, ALT and AST levels can still change during therapy for several reasons:

\n\n

1. Fatty liver disease (NAFLD/MASLD). Men with low testosterone are more likely to have non-alcoholic fatty liver disease. TRT has been studied as a potential therapeutic factor for NAFLD — some meta-analyses suggest that restoring normal testosterone levels may reduce hepatic fat accumulation and improve ALT/AST in hypogonadal men with concurrent NAFLD. A 2025 systematic review in World Journal of Gastroenterology found that testosterone therapy was associated with reduced liver fat content and modest transaminase improvement in this population.

\n\n

2. Concomitant medications and supplements. Men on TRT often take other substances — statins for cardiovascular risk, NSAIDs for joint pain, or supplements not prescribed by their clinician. These are more likely to cause elevated liver enzymes than testosterone itself.

\n\n

3. Alcohol intake. As with any medication, alcohol consumption adds hepatic burden. This is independent of the TRT formulation used.

\n\n

4. Bodybuilding compounds. Men who stack TRT with oral 17-alpha-alkylated anabolic steroids (e.g., in unsupervised fitness contexts) do face significant hepatotoxicity risk. This is a risk of the stacked compounds, not of clinical-dose TRT itself.

\n\n

Monitoring Liver Enzymes on TRT

\n\n

A standard TRT blood work panel should include liver function tests (LFTs) at baseline and during follow-up. Key markers:

\n\n\n\n\n\n\n\n\n

Test	Normal Range (approx)	What It Tells You
ALT (alanine aminotransferase)	7-56 U/L	Liver-specific enzyme; elevated levels suggest hepatocellular injury
AST (aspartate aminotransferase)	10-40 U/L	Found in liver and other tissues; less liver-specific than ALT
ALP (alkaline phosphatase)	44-147 U/L	Elevated in cholestasis or bile duct issues
Total bilirubin	0.1-1.2 mg/dL	Jaundice indicator; elevated in liver or hemolytic conditions
GGT (gamma-glutamyl transferase)	9-48 U/L	Sensitive to alcohol intake and biliary disease

\n\n

The Endocrine Society's clinical practice guidelines recommend baseline metabolic panel evaluation before starting TRT and periodic monitoring thereafter, though the exact cadence depends on the patient's clinical picture. Many responsible TRT clinics check LFTs at 3-6 months after initiation and annually thereafter.

\n\n

What Elevated Liver Enzymes on TRT Should Trigger

\n\n

If your ALT or AST rises during TRT:

\n\n

Mild elevation (1-2x upper limit of normal): Your clinician will likely repeat the test, review other medications and supplements, assess alcohol intake, and evaluate for NAFLD. This is often transient and not TRT-specific.

\n\n

Significant elevation (3-5x upper limit of normal): Further investigation for alternative causes (viral hepatitis, medication-induced liver injury, autoimmune conditions, gallbladder disease) is warranted. TRT is typically continued if it's not the suspected cause, but the clinical picture needs broader workup.

\n\n

Severe elevation (5x+ upper limit of normal): Specialist referral (hepatology or gastroenterology) and potential temporary pause of non-essential medications, which may include TRT depending on the clinical context.

\n\n

Bottom Line

\n\n

The testosterone-liver damage concern is rooted in real historical toxicity from 17-alpha-alkylated oral steroids — compounds that are no longer used in responsible TRT practice. Modern TRT via injections, transdermal gels, and oral testosterone undecanoate does not carry the same hepatotoxicity risk. Liver function tests remain a useful monitoring tool because they can reveal other health issues, track medication interactions, and establish a baseline metabolic picture — not because modern TRT inherently threatens the liver.

\n\n

Men with pre-existing liver disease should discuss their TRT options with a clinician who reviews their full hepatic panel and individual risk factors rather than assuming any testosterone formulation is automatically contraindicated.